Effect of triple inhaled therapy on MACE and cardiovascular events in COPD: a systematic review and meta-analysis
Related Experiment Video
Updated: Jan 8, 2026
Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
A Calderón-Montero1, J de Miguel Díez2, V Barrios3
1Cerro del Aire Primary Care Health Center, SERMAS, Madrid, Majadahonda, Spain.
Background:
Although some meta-analyses show that triple inhaled therapy (TT) reduces all-cause mortality compared with dual inhaled therapy (DT), the effect on cardiovascular events is not yet well defined. We estimated the effect of TT compared with DT (LAMA/LABA or LABA/ICS) on MACE and cardiovascular outcomes in an evidence synthesis.
Methods:
Following prospective registration (https://osf.io/gtfvm), a comprehensive search strategy of PubMed, Scopus, and Embase was performed until 15 January 2025. All randomized clinical trials (RCTs) evaluating TT vs. DT and reporting MACE and cardiovascular outcomes were included. We assessed risk of bias and conducted a random-effects meta-analysis estimating summary relative risk (RR) with 95% confidence intervals, evaluating heterogeneity using I 2. A network meta-analysis (NMA) was undertaken.
Results:
From 781 citations, five RCTs were selected (7,855 patients receiving TT, 7,003 LABA/ICS, 5,059 LAMA/LABA). The risk of bias was moderate in three and low in two RCTs. TT reduced MACE by a non-significant 11% vs. LAMA/LABA (0.89; 0.70-1.12, four RCTs, I 2 = 0%) and increased by a non-significant 26% vs. LABA/ICS (1.26; 0.97-1.64, four RCTs, I 2 = 0%). TT reduced cardiovascular mortality (CVD) by 50% (0.50; 0.31-0.80, three RCTs, I 2 = 0%) and increased non-fatal stroke by 92% (1.92; 1.09-3.39, two RCTs, I 2 = 0%) compared with LAMA/LABA. TT shows a favorable trend in myocardial ischemia outcomes. For CVD, NMA showed that TT ranked first and LAMA/LABA last in effectiveness.
Conclusions:
In exacerbating patients with moderate to very severe COPD, TT significantly reduces CVD compared with LAMA/LABA dual therapy, without a significant reduction in MACE.
Systematic Review Registration:
https://doi.org/10.17605/OSF.IO/GTFVM.
More Related Videos
07:10Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
04:59Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
Published on: May 30, 2025
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:24Asthma-III: Symptoms and Complications
Classification of Asthma
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...